Illumina's very large installed base of sequencing instruments should translate into significant ongoing sales of high-margin consumables and related services.

Illumina's genomic sequencing technology enjoys extensive citations in industry publications, and customer workflows have been developed around its systems that need to be repeated consistently.

It’s been nearly 15 years since San Diego’s Illumina gained supremacy in DNA sequencing — with just a few rivals competing to deliver the equipment and chemistry to map the genome. But that ...

Illumina today announced a series of updates to its NovaSeq X Series, delivering the NovaSeq X single-flow-cell system alongside a cutting-edge software upgrade and new kits.

Illumina's divestiture of GRAIL boosts financials, while strong gross margins and DNA sequencing growth drive potential. See ...

Analysts are divided on Illumina's 2023 prospects after the company reported Q4 results and delivered its first NovaSeq X Plus system.

Illumina Inc., a global leader in DNA sequencing and array-based technologies, today announced that its first product based on its novel Illumina Complete Long Read technology is now available to ...

In recent years, Novogene Europe has systematically integrated state-of-the-art technologies across its service portfolio, ...

Vulnerabilities The flaws exist in machines utilizing Illumina's UCS, a key software that transfers patient data from the DNA sequencing machines to a centralized management architecture.

Grail and several other companies are developing tests, using Illumina's sequencing systems, to detect cancer by looking for fragments of cancer DNA in a patient's blood.

Healthcare - MedLife, the largest private healthcare network in Romania, has announced the acquisition of the advanced ...